Core Point - Algernon Pharmaceuticals Inc. is changing its name to Algernon Health Inc., with shares starting to trade under the new name on October 20, 2025 [1][2]. Group 1: Name Change Details - The new CUSIP number will be 01559C 10 6, while the symbol will remain AGN [3]. - All open orders will be canceled at the end of business on October 17, 2025, and dealers are reminded to re-enter their orders [1][2]. Group 2: Additional Information - Disclosure documents regarding the name change are available at www.thecse.com [1][2].

Core Insights - Algernon Pharmaceuticals has signed a definitive equipment order and financing agreement with Catalyst MedTech for four FDA-cleared Oncovision CareMiBrain™ PET scanner systems, valued at over CAD $4 million, to be used in planned neuroimaging clinics [1][2] - The PET scanners will primarily focus on early-stage detection of Alzheimer's Disease and other neurological conditions, addressing a significant market need [3][4] Financial Terms - The financing agreement includes a 20% deposit, monthly payments at an average annual interest rate of 7%, and a balloon payment after two years [2] - The PET scanner costs represent approximately 80% of the capital required to open a neuroimaging clinic, making this transaction crucial for the company's initiative [2] Market Opportunity - The global economic burden of Alzheimer's was estimated at US$1 trillion in 2019, projected to rise to US$10 trillion by 2050, indicating a substantial market opportunity for Alzheimer's diagnostics and treatment [4] - The recent FDA approval of new Alzheimer's therapies requiring brain-specific PET scans has created a billion-dollar market opportunity in this sector [4] Clinic Operations - The new clinics will be the first dedicated brain-specific PET neuroimaging facilities in the U.S., focusing on early detection of Alzheimer's and other neurological disorders [3] - Each Alzheimer's PET brain scan will cost approximately US$5,000, covered by private insurance, Medicare, and Medicaid [6] Strategic Partnerships - Catalyst MedTech is a leading provider of molecular imaging technology and has secured exclusive distribution rights for the CareMiBrain™ system in the U.S. [7][16] - The partnership will enhance patient access and experience while reducing radiation exposure by up to 25% compared to traditional PET/CT units [8][11] Future Plans - Algernon plans to expand its network of neuroimaging clinics across North America and will soon announce the location of its first U.S. flagship clinic [13] - The company is also changing its name to Algernon Health Inc. to better reflect its focus on Alzheimer's diagnostics [13]

Core Insights - Algernon Pharmaceuticals has signed a definitive equipment order and financing agreement with Catalyst MedTech for four FDA-cleared Oncovision CareMiBrain™ PET scanner systems, valued at over CAD $4 million, to be used in planned neuroimaging clinics [1][2] - The PET scanner represents approximately 80% of the capital costs required to open a neuroimaging clinic, making this transaction crucial for the company's neuroimaging initiative [2] - The clinics will focus on early-stage detection of Alzheimer's Disease and other neurological conditions, addressing a significant market need as nearly 80% of Americans want to know if they have Alzheimer's before symptoms appear [3][4] Financial and Market Opportunity - The global economic burden of Alzheimer's was estimated at US$1 trillion in 2019, projected to rise to US$10 trillion by 2050, creating a substantial market opportunity for brain-specific PET scans and Alzheimer's treatments [4] - Each Alzheimer's PET brain scan will cost approximately US$5,000, with coverage from private insurance, Medicare, and Medicaid [6] - The current number of full-body PET/CT scanners in the U.S. is insufficient to meet the demand for Alzheimer's diagnostics, as 45% of existing scanners are primarily used for cancer and cardiac imaging [5] Technological Advancements - The CareMiBrain™ system is a dedicated brain PET scanner that reduces radiation exposure by up to 25% compared to full-body PET/CT units, enhancing patient safety [8][11] - The system features advanced technology for clarity and quantification, and is designed for patient comfort with ergonomic features [10][16] - Catalyst MedTech will provide consulting services to Algernon, including guidance on regulatory compliance and billing for the clinics [12] Strategic Partnerships and Future Plans - Algernon will collaborate with neurologists, geriatricians, and other medical professionals to generate patient referrals for the new clinics [3] - The company plans to change its name to Algernon Health Inc. to better reflect its focus on Alzheimer's diagnostics and neuroimaging clinics across North America [13] - Further updates on the company's expansion and growth plans, including the location of its first U.S. flagship neuroimaging clinic, will be provided soon [13]

Core Points - Algernon Pharmaceuticals Inc. held its annual and special meeting of shareholders, where a resolution to alter the company's authorized share structure to include an unlimited number of Preferred Shares was approved with over 93% of votes in favor [1] - The Series 1 Preferred Shares will offer a ten percent annual dividend and are convertible into ten Common Shares without payment [2] - The company plans to issue a total of 450,000 Preferred Shares and 450,000 Preferred Warrants related to a recent acquisition, along with 1,268,334 Preferred Shares and 634,167 Preferred Warrants from a private placement [2] - All five nominees for the board of directors were elected with over 95% of votes in favor [3] - The company intends to change its name to Algernon Health Inc. to reflect its focus on Alzheimer's Disease diagnostics and plans to establish specialized neuroimaging clinics across North America [4] Company Overview - Algernon Pharmaceuticals is focused on brain-specific PET scanning services for detecting Alzheimer's disease and other neurological conditions, and is also advancing a psychedelic program for stroke and traumatic brain injury [5] - The company holds a 20% equity position in Seyltx, a U.S.-based drug development company working on a chronic cough drug called Ifenprodil [5]

Core Viewpoint - Algernon Pharmaceuticals Inc. has successfully closed a second tranche of its non-brokered private placement, raising a total of $761,000 from both tranches to support its initiatives, including a new Alzheimer's Disease project [1][3]. Group 1: Offering Details - The second tranche of the private placement was part of an offering initially announced on May 27, 2025, with the first tranche closing on June 30, 2025 [1]. - Insiders of the company participated in the offering, contributing $90,000, which is classified as a related party transaction under Multilateral Instrument 61-101 [2]. - The company did not pay any cash finder's fees for the second tranche of the offering [3]. Group 2: Use of Proceeds - Proceeds from the second tranche will be allocated towards advancing the company's Alzheimer's Disease initiative, including the opening of its first U.S. neuroimaging clinic planned for Q4 2025, as well as for general administrative expenses and working capital [3]. Group 3: Company Overview - Algernon Pharmaceuticals is focused on establishing Alzheimer's screening, imaging, and treatment clinics in North America while also developing clinical-stage pharmaceuticals to address unmet medical needs globally [7]. - The company is the parent of a private subsidiary, Algernon NeuroScience, which is investigating a proprietary form of DMT for stroke and traumatic brain injury [8].

Core Viewpoint - Algernon Pharmaceuticals Inc. has successfully completed the acquisition of 100% of NoBrainer Imaging Centers, Inc., marking its entry into the Alzheimer's Disease diagnostic and treatment market, while expanding its existing neurological research programs [2][3]. Company Overview - Algernon Pharmaceuticals is a Canadian healthcare and clinical stage drug development company focused on addressing unmet global medical needs through various drug investigations [13]. Acquisition Details - The acquisition of NoBrainer Imaging Centers, Inc. provides Algernon exclusive master franchise and licensing rights to establish Alzheimer's Disease screening, diagnostic, and treatment centers across Canada and in several U.S. markets [2][3]. - The transaction was finalized following share exchange agreements with NIC and its shareholders, allowing Algernon to acquire all common and preferred shares of NIC [3]. Financial Considerations - The final consideration for the acquisition includes the issuance of 5,500,000 common shares and warrants, as well as 450,000 preferred shares and warrants, subject to shareholder approval [4][9]. - NIC has CAD$250,000 in working capital, which includes a deposit for a Positrigo NeuroLF brain-specific PET scanner, expected to be delivered to the first U.S. clinic in Q4 2025 [3]. Shareholder Approval and Securities - Algernon plans to expedite its annual meeting to seek shareholder approval for the issuance of preferred shares and related securities within six months [9]. - The securities issued will be subject to a statutory hold period, with financial statements reflecting the acquisition expected to be filed by July 30, 2025 [11].

Core Viewpoint - Algernon Pharmaceuticals Inc. has announced an extension of the expiry date for 4,752,969 outstanding warrants, originally set to expire on May 5, 2025, now extended to November 5, 2025, with the exercise price remaining at $0.52 [1][2]. Summary by Sections Warrants Details - The 2023 Warrants were initially set to expire on November 5, 2024, and were previously extended to May 5, 2025, now further extended by six months to November 5, 2025 [2]. - The exercise price of the 2023 Warrants remains unchanged at $0.52 [2]. Regulatory Approval - The Amendment to extend the expiry date is subject to final approval from the Canadian Securities Exchange (CSE), which has granted an exemption from certain requirements to allow the Amendment [3]. - No action is required from the holders of the 2023 Warrants for the Amendment to take effect [3]. Insider Holdings - Out of the 2023 Warrants, 400 have been exercised, with no exercises occurring in the last six months [4]. - Insiders hold 2,018,982 of the 2023 Warrants, representing 42.5% of the total [4]. - The Amendment may be considered a "related party transaction" under Multilateral Instrument 61-101, but is exempt from formal valuation and minority shareholder approval requirements [4]. Company Overview - Algernon Pharmaceuticals is a Canadian clinical stage pharmaceutical development company focused on addressing unmet global medical needs [6]. - The company also has a subsidiary, Algernon NeuroScience, which is advancing a psychedelic program involving a proprietary form of DMT for stroke and traumatic brain injury [6].